Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Menopause
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Menopause
    TopAbstracts in Menopause 10/27/2009 - (DGNews)
    TopAbstracts in Menopause 10/13/2009 - (DGNews)
    Novel Administration Method for Hormone Therapy May Offer Increased Safety, Other Benefits: Presented at NAMS - (DGDispatch)
    Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen - (JAMA)
    Fewer and Less Severe Hot Flushes Experienced With Experimental SERM: Presented at NAMS - (DGDispatch)

    News archive

     Recent webcasts/CME - Menopause
      Issues in Postmenopausal Hormone Therapy
      The Council on Menopause Management Video: Clinical Challenges and Quality of Life Issues
      How to Appropriately Counsel and Manage a Recently Menopausal Woman Worried About the Safety of Hormone Therapy
      Endocrinology and Management of Hormone Therapy in Older Women
      Endocrinology and Management of Hormone Therapy in Older Women

      Webcasts/CME archive

       Recent cases - Menopause
        Giant Ovarian Serous Cystadenoma in a Postmenopausal Woman: A Case Report
        Spontaneous Perforated Pyometra with an Intrauterine Device in Menopause: a Case Report
        Female Sexual Dysfunction
        Female Sexual Dysfunction: Does Surgically Induced Menopause Matter?
        A Postmenopausal Woman Presenting with Atypical Symptoms and Cervical Cancer : A Case Report

        Cases archive
          




        my personal edition > menopause > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Weekly Risedronate Gets Similar Bone Mineral Density Results to Daily Formulation: Presented at AACE

        By Paula Moyer

        SAN DIEGO, CA -- May 20, 2003 -- Postmenopausal women who take weekly risedronate (Actonel) get equivalent bone antiresorptive benefits as patients who use the daily dosing regimen.

        "These results are encouraging because the once-weekly regimen is very popular and convenient," said Earl W. Sod, PhD, senior scientist in clinical development, musculoskeletal division, Procter & Gamble Pharmaceuticals, Mason, Ohio. The principal investigator in the study was Robert R. Recker, MD, an endocrinology fellow, Creighton University, Omaha, Neb.

        "Because the daily and weekly dosing regimens produce similar results, physicians can comfortably offer the 35 mg once-weekly formulation as an alternative to 5 mg daily dosing," Dr. Sod said.

        Drs. Sod and Recker presented the findings here on May 16th at the American Association of Clinical Endocrinologists 12th Annual Meeting and Clinical Congress. They designed their study to compare the efficacy of a daily dose of risedronate, consisting of 5 mg, with 2 weekly formulations -- one at 35 mg weekly, and the other at 50 mg weekly. The study population consisted of 109 women with postmenopausal osteoporosis.

        The primary aim was to assess changes in bone mineral density (BMD) in the lumbar spine at 1 year, and to assess safety for the 2-year study period. The subjects were randomized to either the weekly or the daily dose.

        Patients' lumbar spine BMD changes were equivalent in both of the weekly dose groups, and the daily group. "This finding," said Dr. Sod, "led the investigative team to conclude that both of the weekly doses were as efficacious as the daily dose of antiresorptive therapies."

        "To assess safety, the investigators obtained iliac-crest biopsy specimens from all participants at baseline, and for 86 participants at year 2. Patients received regional anesthesia for the biopsy procedures," Dr. Sod said.

        The investigators found no histological abnormalities in any of the treatment groups. The investigators concluded that this finding implied normal bone quality, even in patients who received the highest dose.

        "There were double tetracycline-labeled surfaces in all end pointbiopsy specimens. Trabecular and cortical bone structural variables were generally unchanged, and similar among all groups. Among participants in the 3 dosing groups, the bone turnover was reduced by approximately 65%, a significant reduction," Dr. Sod said.

        He and his colleagues found increased bone formation periods in all the treatment groups, and found significant increases in the daily group, and the 35 mg weekly group. These findings were confirmatory of previous data for 5 mg of risedronate daily, according to Dr. Sod. They found that the median mineralizing surface was approximately 1.5% in all groups after 2 years of therapy.

        Median change in mineral apposition rate (MAR) was positive in all groups, and significantly so in the weekly-dosing groups. Although no groups had changes in bone wall thickness, the investigators inferred that risedronate had an anabolic effect, due to the increased MAR and bone formation periods.

        This study was sponsored by Procter & Gamble Pharmaceuticals, Mason, Ohio.


        [Study title: Bone Histology And Histomorphometry in a 2-Year Risedronate Study Comparing Daily and Weekly Dosing. Abstract 67]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send